Related Experiment Video
Updated: Feb 12, 2026

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
Intensive haemodialysis using PMMA dialyser does not increase renal response rate in multiple myeloma patients with
Laurent Hudier1, Olivier Decaux2,3,4,5,6,7,8,9,10,11, Atmann Haddj-Elmrabet3
1Centre hospitalier Broussais, Service de Néphrologie-Hémodialyse, Saint-Malo, France.
Background:
Intensive haemodialysis (IHD) in addition to bortezomib-based chemotherapy might be efficient to rapidly decrease serum immunoglobulin-free light chains removal in patients with multiple myeloma (MM) and to improve renal prognosis and survival.
Methods:
The aim of this retrospective multi-centre study was to compare the efficacy (renal recovery rate) of IHD and of standard haemodialysis (SHD) in patients with MM and dialysis-dependent acute kidney injury (AKI), concomitantly treated with bortezomib-based chemotherapy.
Results:
We selected 41 patients with MM and dialysis-dependent AKI, most likely due to myeloma cast nephropathy (MCN), and who were treated in eight French hospitals between January 2007 and June 2011. Patients were classified in two groups according to dialysis regimen: IHD [n = 21, with a mean of 11.3 dialysis sessions all with poly(methyl methacrylate) (PMMA) membranes for 13.2 days] and SHD (n = 20 patients, mostly three times per week, 31% with PMMA membrane). The main outcome was dialysis-independence at 3 months. At 3 months, 15 patients could stop dialysis: 8 (38.1%) in the IHD and 7 (35%) in the SHD group (P = 1). Moreover, 14 (56%) of the 25 patients who did show haematological response and only one of the 16 patients who did not were dialysis-independent (P = 0.002) at 3 months.
Conclusions:
The results of this retrospective study did not show any clear renal benefit of IHD in patients with MM and MCN compared with SHD. Conversely, they underline the importance of the haematological response to chemotherapy for the renal response and patient prognosis.
Insights
Intensive haemodialysis (IHD) did not show a renal benefit over standard haemodialysis (SHD) for multiple myeloma (MM) patients with acute kidney injury. Achieving a hematologic response to chemotherapy was crucial for kidney recovery and improved patient survival.
Area of Science:
- Nephrology
- Hematology
- Oncology
Background:
- Multiple myeloma (MM) patients with acute kidney injury (AKI) may benefit from intensive hemodialysis (IHD) for rapid reduction of serum free light chains.
- IHD alongside bortezomib-based chemotherapy could potentially improve renal outcomes and survival in MM patients.
Purpose of the Study:
- To compare the efficacy of IHD versus standard hemodialysis (SHD) in MM patients with dialysis-dependent AKI undergoing bortezomib-based chemotherapy.
- To evaluate the renal recovery rate as the primary outcome measure.
Main Methods:
- Retrospective, multi-center study involving 41 MM patients with dialysis-dependent AKI.
- Patients were divided into two groups: IHD (n=21) and SHD (n=20).
- Primary endpoint was dialysis independence at 3 months.
Main Results:
- No significant difference in dialysis independence at 3 months between IHD (38.1%) and SHD (35%) groups (P=1).
- A significant association was observed between hematologic response to chemotherapy and dialysis independence (56% vs 6.3%, P=0.002).
- The type of dialysis did not influence renal recovery in this cohort.
Conclusions:
- Intensive hemodialysis (IHD) did not demonstrate a clear renal benefit compared to standard hemodialysis (SHD) in multiple myeloma patients with myeloma cast nephropathy.
- Hematologic response to chemotherapy is a critical factor for renal recovery and overall prognosis in these patients.
- Further research may be needed to explore optimal dialysis strategies in MM-related AKI.
Related Concept Videos
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury III: Clinical Manifestations
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...

